The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma.
about
Oncolytic viruses as therapeutic cancer vaccinesIntelligent design: combination therapy with oncolytic virusesOncolytic viruses: finally deliveringViruses as nanomedicine for cancerNovel Immunotherapeutic Approaches for Head and Neck Squamous Cell CarcinomaTargeting tumor vasculature with an oncolytic virus.Functional hyper-IL-6 from vaccinia virus-colonized tumors triggers platelet formation and helps to alleviate toxicity of mitomycin C enhanced virus therapyReplication and Oncolytic Activity of an Avian Orthoreovirus in Human Hepatocellular Carcinoma Cells.Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future PerspectivesOncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model.Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer.Bacterial-mediated knockdown of tumor resistance to an oncolytic virus enhances therapy.Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF.Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors.Synergistic interaction between oncolytic viruses augments tumor killing.Bacterial glucuronidase as general marker for oncolytic virotherapy or other biological therapiesThe combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host.Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancerEfficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma.Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacyOncolytic Poxviruses.Histological evaluation of intratumoral myxoma virus treatment in an immunocompetent mouse model of melanoma.New frontier in liver cancer treatment: oncolytic viral therapy.Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice.TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer.Oncolytic poxvirus armed with Fas ligand leads to induction of cellular Fas receptor and selective viral replication in FasR-negative cancer.Oncolytic virotherapy for advanced liver tumours.Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity.Effective oncolytic vaccinia therapy for human sarcomas.A marker-free system for highly efficient construction of vaccinia virus vectors using CRISPR Cas9.Antitumour responses induced by a cell-based Reovirus vaccine in murine lung and melanoma modelsHarnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine.A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication.Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects.Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal CancerEffect of respiratory syncytial virus on the growth of hepatocellular carcinoma cell-linesA cancer-favoring oncolytic vaccinia virus shows enhanced suppression of stem-cell like colon cancer.Primary human leukocyte subsets differentially express vaccinia virus receptors enriched in lipid rafts.Vaccinia virus, a promising new therapeutic agent for pancreatic cancer.
P2860
Q21245758-32C6FE33-FBD0-4B6D-B109-DB1DF749FF60Q24628227-A34122C4-ADCA-463C-A0BE-95785D8A8FBBQ26772039-285110E9-916E-4784-BA70-7D9210D9849CQ27690636-D09FF0ED-80C3-4D1C-82F6-9C4E66C6BC71Q28071998-638E8CD9-0419-4134-8B66-3850BC760354Q30500348-95BD1A77-9E5C-4045-9AEF-752168AF06CCQ33399140-593390E2-98F0-4482-83BE-36B8BE12B44BQ33613549-13B0F742-0E35-4073-8906-154794BD3BBDQ33679505-024B51BD-6F8F-41B0-9594-6DDB003ECB6CQ33710420-53FA50A2-46BD-4185-A7FA-E8B9A94EF4ECQ33713908-E38EB0F1-4C06-4973-B814-0D1F1CAB266CQ33724207-6BE95C2F-612A-42BF-A2A5-1ECDAB169607Q33769835-A9803106-B4D0-4D60-94D0-3DCCD3ADC513Q33808504-ABB212C3-57D7-4E5C-8F93-10EFB4B5A185Q33931616-8E569A54-E417-4E1F-B5F7-F4D0D6105DA0Q34223150-BDB34108-2393-4CFA-A016-C09B0CB58968Q34316241-BD9DAA71-9FC4-468A-B2D0-838481BD5C38Q34327051-505A8130-43C3-4516-92EA-CDF81DE15AE3Q34343768-8584AF8C-7037-42D0-B321-1AD864D48AC5Q35086690-4F967CF2-F2EA-40F3-820B-C252942E72E5Q35234349-B87D4D12-0700-4421-91CD-A9F7E7DC4449Q35317396-449514AC-9F1B-47FB-8DD1-8E891F727865Q35593720-066B15DF-6886-4102-BCFC-55552F827B24Q35623101-78C5C7D2-F03B-415E-8DFC-5E36EC2EBAB4Q35647212-94F79EFB-5F54-48D0-8F27-29EA7CE05C38Q35783456-366F8360-026A-4965-93C3-751DD4C748B7Q35832074-036C8195-A6ED-466B-89F6-0F987B9783D7Q35876239-7320AD3C-D1E0-4CA3-9EFC-27CCB2B7C31CQ35954052-E1922B6A-BE0D-44CB-9B9D-81A74F0BDF24Q36064702-786521A5-927E-421A-B906-EC606B69F065Q36076671-1C2A868D-7B3D-495D-AEDD-0751F45FD8FEQ36220618-72FF9C16-8AB3-46A2-B074-3D877865DF5DQ36391900-7626AB46-B403-433E-ADE9-F41CE8683CC8Q36659289-2C319396-2157-4FD1-81D3-DE9A7B5A7716Q36700481-1EEDD36F-83F9-4FF3-A1D5-7FAC99B6495BQ36757045-81F8375D-F44C-48FF-9B4E-14DFE058B59FQ37013811-F6F9FAB6-015F-4D74-B924-41B3F1B1BA52Q37086063-D7E61BDF-944C-4A35-B244-7FE57399DE4CQ37123323-E8819436-9FFC-4C03-91DE-6ECCC9C2C3D6Q37158473-3F61EA5B-0E73-47CF-B927-5909504E2AB2
P2860
The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
The targeted oncolytic poxviru ...... with hepatocellular carcinoma.
@en
The targeted oncolytic poxviru ...... with hepatocellular carcinoma.
@nl
type
label
The targeted oncolytic poxviru ...... with hepatocellular carcinoma.
@en
The targeted oncolytic poxviru ...... with hepatocellular carcinoma.
@nl
prefLabel
The targeted oncolytic poxviru ...... with hepatocellular carcinoma.
@en
The targeted oncolytic poxviru ...... with hepatocellular carcinoma.
@nl
P2093
P356
P1433
P1476
The targeted oncolytic poxviru ...... with hepatocellular carcinoma.
@en
P2093
Byeong-Ho Park
David H Kirn
Ta-Chiang Liu
Taeho Hwang
P304
P356
10.1038/MT.2008.143
P50
P577
2008-07-15T00:00:00Z